Company intelligence / Profile preview

GenEmbryomics

Point Cook, Victoria, Australia

Ownership: Private
Development stage: Preclinical

Overview

GenEmbryomics has developed Panacea GenomeScreen™, a proprietary whole genome sequencing-based preimplantation genetic test that screens embryos and parents for over 3,200 severe and fatal inherited or de novo mutations. The technology aims to provide more comprehensive risk assessment than standard chromosomal aneuploidy tests. Clinical rollout is planned following ongoing validation studies and partnerships with IVF clinics globally. No published clinical trial results yet.

Therapeutic areas: Rare DiseasesWomen's Health
Modalities: DNA sequencing-based diagnosticsWhole genome sequencing
Industry: Molecular Diagnostics

Drug pipeline

4 assets

Panacea-GenomeScreen

Pre-clinical

Indications: IVF embryo screening

3 more assets in the full pipeline.

Request access →

Partnerships

ProgenesisQualioCompliancy Group

Beyond the preview

Go deeper on GenEmbryomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenEmbryomics.

Explore the full profile